US6374762B1
(en)
*
|
1997-10-27 |
2002-04-23 |
Correct Craft, Inc. |
Water sport towing apparatus
|
ES2193875B2
(en)
*
|
2002-04-09 |
2005-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
|
US20040242572A1
(en)
*
|
2002-08-24 |
2004-12-02 |
Boehringer Ingelheim International Gmbh |
New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
PL217630B1
(en)
|
2003-04-24 |
2014-08-29 |
Incyte Corp |
Aza spiro alkane derivatives as inhibitors of metalloproteases
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
US20060122197A1
(en)
*
|
2004-08-10 |
2006-06-08 |
Wenqing Yao |
Amido compounds and their use as pharmaceuticals
|
EP1781288A2
(en)
|
2004-08-19 |
2007-05-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
US7786141B2
(en)
*
|
2004-08-19 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Dihydrospiroindene modulators of muscarinic receptors
|
AU2005280921B2
(en)
*
|
2004-09-07 |
2011-05-19 |
Msd K.K. |
Carbamoyl-substituted spiro derivative
|
NZ555444A
(en)
*
|
2004-11-29 |
2011-01-28 |
Vertex Pharma |
Modulators of muscarinic receptors
|
CN101277960A
(en)
|
2005-09-29 |
2008-10-01 |
默克公司 |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
CA2629018C
(en)
*
|
2005-11-10 |
2013-12-31 |
Banyu Pharmaceutical Co., Ltd. |
Aza-substituted spiro derivative
|
CN101305009B
(en)
*
|
2005-11-10 |
2012-01-11 |
Msdk.K.公司 |
Aza-substituted spiro derivative
|
RU2008130094A
(en)
*
|
2005-12-22 |
2010-01-27 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
MUSCARINE RECEPTOR MODULATORS
|
CN101426499A
(en)
|
2006-02-22 |
2009-05-06 |
弗特克斯药品有限公司 |
Modulators of muscarinic receptors
|
WO2007100670A1
(en)
|
2006-02-22 |
2007-09-07 |
Vertex Pharmaceuticals Incorporated |
Spiro condensed piperidnes as modulators of muscarinic receptors
|
WO2007143600A2
(en)
|
2006-06-05 |
2007-12-13 |
Incyte Corporation |
Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
|
CA2656183A1
(en)
*
|
2006-06-29 |
2008-01-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
CN101553231A
(en)
*
|
2006-08-15 |
2009-10-07 |
弗特克斯药品有限公司 |
Modulators of muscarinic receptors
|
CA2660974A1
(en)
*
|
2006-08-18 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
US8173629B2
(en)
|
2006-09-22 |
2012-05-08 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
AU2008307440A1
(en)
*
|
2007-10-03 |
2009-04-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
US8383629B2
(en)
*
|
2008-02-27 |
2013-02-26 |
Vitae Pharmaceuticals, Inc. |
Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
|
CA2930674A1
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
JP2011528375A
(en)
|
2008-07-16 |
2011-11-17 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
|
CN102264228A
(en)
|
2008-10-22 |
2011-11-30 |
默沙东公司 |
Novel cyclic benzimidazole derivatives useful for anti-diabetic agents
|
JP5635991B2
(en)
|
2008-10-30 |
2014-12-03 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonist
|
AU2009309037A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2011069298A1
(en)
|
2009-12-11 |
2011-06-16 |
F. Hoffmann-La Roche Ag |
Novel cyclopropane indolinone derivatives
|
CN102656147A
(en)
*
|
2009-12-11 |
2012-09-05 |
霍夫曼-拉罗奇有限公司 |
Spiro indole-cyclopropane indolinones useful as AMPK modulators
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
ES2652662T3
(en)
|
2011-02-25 |
2018-02-05 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents
|
AR088352A1
(en)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
|
US20130303509A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Nampt inhibitors
|
SG10201610416TA
(en)
|
2012-06-13 |
2017-01-27 |
Incyte Corp |
Substituted tricyclic compounds as fgfr inhibitors
|
AU2013296470B2
(en)
|
2012-08-02 |
2016-03-17 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
MX2015010935A
(en)
|
2013-02-22 |
2015-10-29 |
Merck Sharp & Dohme |
Antidiabetic bicyclic compounds.
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
JP2016514670A
(en)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Guanylate cyclase receptor agonists in combination with other drugs
|
SI2986610T1
(en)
|
2013-04-19 |
2018-04-30 |
Incyte Holdings Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
JP6606491B2
(en)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
MA41551A
(en)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
|
MX2020004108A
(en)
|
2015-02-20 |
2022-01-03 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors.
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
WO2018106518A1
(en)
|
2016-12-06 |
2018-06-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
AR111960A1
(en)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
|
WO2019213544A2
(en)
|
2018-05-04 |
2019-11-07 |
Incyte Corporation |
Solid forms of an fgfr inhibitor and processes for preparing the same
|
TW201946630A
(en)
|
2018-05-04 |
2019-12-16 |
美商英塞特公司 |
Salts of an FGFR inhibitor
|
WO2020167706A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
IL291901A
(en)
|
2019-10-14 |
2022-06-01 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
EP4200295A1
(en)
|
2020-08-18 |
2023-06-28 |
Merck Sharp & Dohme LLC |
Bicycloheptane pyrrolidine orexin receptor agonists
|
CN112939864B
(en)
*
|
2021-01-29 |
2022-05-06 |
中国医科大学 |
Spiro [ benzo [ c ] aza-1, 1' -cyclohexyl ] -3-ones
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|